Incremental benefits of novel pharmaceuticals in the United Kingdom 73 4♣ 3 Erroneous redaction Supplementary Figure 5: Erroneous redaction of cost only from TA192: Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer. Table from the Advisory Committee Decision Pre-meeting Briefing Supplementary Figure 6: Erroneous redaction of cost only from TA487: Venetoclax for treating chronic lymphocytic leukaemia. Table from the Public Committee Slides Final Appraisal Determination.
RkJQdWJsaXNoZXIy MTk4NDMw